Nuffield Department of Population Health

Study Designs Completed for NIH Consortium Study of Long-term COVID-19

Wednesday, September 15, 2021 - 4:41pm

As the CSC for the NIH grant, NYU Langone is charged with integrating the research activities of clinical sites around the country.

Key Points: 
  • As the CSC for the NIH grant, NYU Langone is charged with integrating the research activities of clinical sites around the country.
  • As of August 25, more than 39 million Americans had been infected with COVID-19, resulting in 648,000 deaths.
  • The study will also seek to enroll participants without SARS-CoV-2 infection to serve as a comparison group.
  • An important aspect of the RECOVER Initiative is the development of the pediatric main protocol for study of Long COVID in children.

ImmunOs Therapeutics Appoints Jeffrey Abbey as Chief Operating Officer, Establishes Clinical Advisory Board

Wednesday, September 1, 2021 - 9:00am

September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.

Key Points: 
  • September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.
  • Under Mr. Abbeys leadership, Argos Therapeutics successfully completed an IPO on NASDAQ, as well as a pivotal Phase 3 clinical trial in kidney cancer.
  • I am looking forward to working with the team at ImmunOs and its advisory boards, said Jeffrey Abbey, MBA, JD, COO of ImmunOs Therapeutics.
  • ImmunOs Therapeutics lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and activates anti-tumor responses.

The Family Health Centers at NYU Langone Receives $2 Million CDC Grant to Expand Effective HIV Prevention

Wednesday, August 4, 2021 - 6:58pm

BROOKLYN, N.Y., Aug. 4, 2021 /PRNewswire/ -- Affirming the success of its HIV prevention programs and support strategies, the Family Health Centers at NYU Langone has received an additional five-year, $2 million grant through the Centers for Disease Control and Prevention's (CDC) Comprehensive High-Impact HIV Prevention Programs for Community Based Organizations.

Key Points: 
  • BROOKLYN, N.Y., Aug. 4, 2021 /PRNewswire/ -- Affirming the success of its HIV prevention programs and support strategies, the Family Health Centers at NYU Langone has received an additional five-year, $2 million grant through the Centers for Disease Control and Prevention's (CDC) Comprehensive High-Impact HIV Prevention Programs for Community Based Organizations.
  • "This competitive grant validates the progress and potential of our outreach efforts to prevent HIV and support our community," says Larry K. McReynolds , executive director of the Family Health Centers at NYU Langone and clinical associate professor in the Department of Population Health at NYU Grossman School of Medicine.
  • "For more than 30 years, the Family Health Centers at NYU Langone has been at the forefront of HIV care and prevention," says Finn Schubert, network HIV program director at the Family Health Centers at NYU Langone.
  • HIV prevention partnership with Turning Point Brooklyn , which provides education, housing, and related servicesin the Sunset Park, Brooklyn, community.